The VP.S ENCORE™ Device is designed to extend the viability of organs outside the body beyond the current standard of care (SOC) which uses ice cooling.
The VP.S ENCORE™ Device, with patents pending, has received a Breakthrough Device Designation from the FDA. The Breakthrough Device Designation is designed to facilitate communications between the company and the FDA to ideally accelerate the device to market.
The VP.S ENCORE™ is a device that can be modified to eventually extend the preservation of other organs and vascularized tissue. Future uses include the use of ex vivo therapies, and ideally provide a foundation for organ banking.
The impact in developing the VP.S ENCORE™ device promises to be significant once data are gathered to demonstrate that this technology can expand the donor pool, resulting in optimized organ matching with less rejection such as primary graft dysfunction.
In addition, the VP.S ENCORE™ device has a rugged design that is easy to transport, and should the device fail for any reason, the device reverts to the standard of care (static cooling).